Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746456 · ClinicalTrials.gov registry record
Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 210
- Enrollment target
NCT04746456: Completed study, sponsored by Massachusetts General Hospital.
NCT04746456 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 210 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746456 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 210 participants
- Enrollment target
Study Summary
The goal of this study is to perform a quantitative assessment of the psychometric properties of the Vulvovaginal Atrophy Questionnaire (VVAQ), a novel patient reported outcome measure (PROM), through a REDCap survey of menopausal women with and without symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM).
Primary Outcome
Results of REDCap survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2024-05-01 |
What the finished NCT04746456 record still lists
NCT04746456 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04746456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04746456 about?
NCT04746456 is a clinical study titled "Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM". The goal of this study is to perform a quantitative assessment of the psychometric properties of the Vulvovaginal Atrophy Questionnaire (VVAQ), a novel patient reported outcome measure (PROM), through a REDCap survey of menopausal women with and without symptomatic vulvovaginal atrophy (VVA)/genitou...
What is the current status of trial NCT04746456?
This trial is currently completed. The enrollment target is 210 participants. The study started on 2022-09-01. Estimated completion is 2024-05-01.
Who is sponsoring clinical trial NCT04746456?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI